


RADIANCE-HTN SOLO 6 MONTH RESULTS



RADIANCE

Evaluation of the Paradise System in Hypertension



The **RADIANCE-HTN SOLO** study is the first blinded, sham-controlled assessment of the blood pressure (BP) reduction effect of the Paradise Renal Denervation System in patients with hypertension.



RADIANCE-HTN SOLO met its 2 Month primary endpoint, demonstrating a greater reduction in BP in treatment arm vs the sham arm. The SOLO 6 Month “on-meds” data assessed the effect of BP reduction in the presence of added anti-hypertension medications.

SAFETY

At 6 months, patients treated with the Paradise® System showed no major safety issues.

DURABILITY

The blood pressure lowering effect of treatment vs. sham, first demonstrated at 2 months, was maintained through 6 months.



At 6 months, RADIANCE-HTN SOLO study demonstrated a greater reduction in blood pressure in treatment arm vs. sham arm.

MKT-0117(A), DCO 0976, Effective Date: April 29, 2019



The PARADISE® system is approved for sale in markets regulated by the CE mark. Investigational Device in the US, Limited by US Federal Law to Investigational Use Only in the United States Data presented at ACC 2019. Published in Circulation 2019 Mar 17, Azizi, M., et.al. <https://doi.org/10.1161/CIRCULATIONAHA.119.040451>

recormedical.com

ReCor Medical
Ultrasound Denervation Therapies


OVERALL TREATMENT EFFECT

More than twice as many patients were on zero medications at 6 months vs. sham (34.8% vs 15.5%).



At 6 months, Paradise Renal Denervation plus medication led to more patients with larger blood pressure drops.

PARADISE RENAL DENERVATION + MEDICATIONS



When stratified by medication, patients treated with the Paradise system had greater blood pressure reduction than sham controls.